Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRONIDAZOLE vs ANOQUAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Trichomoniasis,Bacterial vaginosis,Amebiasis,Giardiasis,Anaerobic bacterial infections (e.g., intra-abdominal, gynecologic, skin and soft tissue, bone and joint, CNS infections),Helicobacter pylori eradication (in combination therapy),Perioperative prophylaxis for colorectal surgery,Acute diverticulitis,Crohn's disease (off-label),Rosacea (topical),Decubitus ulcers (topical)
Hypertension
500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.
100 mg orally twice daily
8 hours (range 6-10 hours) in adults; prolonged to 18-20 hours in severe hepatic impairment; requires adjustment in cirrhosis.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic metabolism via oxidation and glucuronidation; major cytochrome P450 enzymes: CYP2A6, CYP3A4, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1; also reduced by nitroreductases in some bacteria and human cells.
Hepatic metabolism via oxidation and conjugation; metabolites excreted renally.
Renal (60-80% unchanged drug), biliary/fecal (6-15% as metabolites, <20% unchanged).
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
<20% bound to plasma proteins (albumin).
Approximately 90% bound to albumin.
0.7-1.1 L/kg; Vd increased in edema/ascites; distributes widely including CNS, bone, and abscess cavities.
0.8-1.2 L/kg, indicating extensive distribution into total body water.
Oral: 80-95% (100% for immediate-release); Topical: <2% systemic; Vaginal: 20-25% systemic after 500 mg dose.
Oral: 60-70% due to first-pass metabolism.
For GFR 10-50 m L/min: no adjustment needed; for GFR <10 m L/min: extend interval to every 12 hours if using multiple doses; for intermittent hemodialysis: administer dose after dialysis on dialysis days.
GFR 30-50 m L/min: 100 mg once daily; GFR <30 m L/min: 50 mg once daily; not recommended for GFR <15 m L/min
For Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider further dose reduction (e.g., 50% of normal dose every 12 hours) and monitor for toxicity.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: not recommended
Neonates: 15 mg/kg loading dose, then 7.5 mg/kg every 12 hours for <7 days, or every 8 hours for 7-28 days; Infants and children: 7.5 mg/kg every 6 hours (max 4 g/day) for most infections; for amebiasis: 35-50 mg/kg/day in 3 divided doses for 10 days.
Not approved for pediatric use; no established dosing
No specific dose adjustment based solely on age, but monitor renal function; reduce dose if creatinine clearance <10 m L/min as per renal adjustment; use lowest effective dose and monitor for neurotoxicity (e.g., peripheral neuropathy, seizures).
No specific adjustment; monitor renal function and consider reduced initial dose (50 mg twice daily) in patients >65 years with renal impairment
Carcinogenicity has been observed in mice and rats following chronic administration; however, the relevance to humans is unclear.
No FDA black box warning.
May cause peripheral neuropathy and CNS effects including seizures, dizziness, and ataxia; discontinue if abnormal neurologic signs occur.,Carcinogenicity in animal studies; use for shortest duration necessary.,Hepatotoxicity and pancreatitis reported.,Hypersensitivity reactions including Stevens-Johnson syndrome.,May prolong QT interval; use with caution in patients with electrolyte disturbances or taking other QT-prolonging drugs.,Potential for disulfiram-like reaction with alcohol; avoid during therapy and for at least 48 hours after completion.,Possible mutagenicity; avoid use in pregnancy (especially first trimester) unless clearly needed.,May cause metallic taste, nausea, and other GI disturbances.
Rebound hypertension upon abrupt discontinuation; sedation and drowsiness; potential for orthostatic hypotension; caution in patients with severe coronary insufficiency or cerebrovascular disease.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (theoretical risk, though risk appears low),Concomitant use with disulfiram (can cause acute psychosis/confusion),Concomitant use with ethanol or propylene glycol (disulfiram-like reaction)
Known hypersensitivity to guanabenz; patients with severe hepatic or renal impairment.
Avoid alcohol and alcohol-containing foods (e.g., sauces, vinegars, some desserts) during therapy and for 48 hours after completion. No other significant food interactions.
Avoid grapefruit and grapefruit juice as they may increase quinine levels. Take with a full glass of water. May be taken with meals to reduce nausea.
Metronidazole crosses the placenta. First trimester: limited human data show no consistent increase in major malformations; however, some studies suggest a possible small risk of oral clefts. Second/third trimester: generally considered low risk; no known fetal toxicity at standard doses. Avoid high doses in first trimester unless essential.
Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and third trimester exposure is associated with fetal nephrotoxicity, oligohydramnios, and premature closure of the ductus arteriosus.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Peak milk concentration occurs 2-4 hours after dose. After single 2 g dose, withholding breastfeeding for 12-24 hours is recommended. Chronic use: monitor infant for diarrhea, candidiasis, or irritability.
Excreted in human milk. M/P ratio not determined. Avoid breastfeeding due to potential for serious adverse reactions in the nursing infant, including renal impairment and electrolyte disturbances.
No specific dose adjustment required in pregnancy; pharmacokinetics unchanged. Standard adult dosing applies. For bacterial vaginosis: 500 mg PO BID x 7 days or 2 g single dose. Avoid high-dose regimens (e.g., for trichomoniasis) in first trimester; use clotrimazole locally if possible.
Anoquan is contraindicated in pregnancy; no dose adjustments are recommended because use during pregnancy is not advised.
Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It requires acidic environment for activation; thus, avoid concurrent use with antacids or H2 blockers. Monitor for peripheral neuropathy and seizure with prolonged use. Disulfiram-like reaction occurs with alcohol; counsel patients to avoid alcohol during therapy and for 48 hours after last dose. Use caution in hepatic impairment (dose reduction recommended). Intravenous form is irritant; do not co-administer with blood products via same line.
ANOQUAN (quinine sulfate) is used for uncomplicated Plasmodium falciparum malaria. Monitor for cinchonism (tinnitus, headache, nausea). Avoid in G6PD deficiency due to hemolysis risk. Correct hypoglycemia frequently. Use with caution in atrial fibrillation due to QT prolongation.
Avoid alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Take with food to minimize gastrointestinal upset.,Complete the full course even if symptoms improve.,Report numbness, tingling, or seizures immediately.,May cause metallic taste (harmless) and darkening of urine (not clinically significant).
Take with food to reduce gastrointestinal upset.,Complete full course even if symptoms improve.,Report ringing in ears, confusion, or vision changes.,Avoid driving if dizziness or visual disturbances occur.,Inform doctor of any history of G6PD deficiency or cardiac arrhythmias.
"Metronidazole is a known inhibitor of CYP3A4, the primary enzyme responsible for metabolizing Osimertinib. Coadministration increases Osimertinib AUC by approximately 30-60%, leading to elevated plasma concentrations that may potentiate adverse effects such as QTc prolongation, interstitial lung disease, and diarrhea. Clinicians should monitor for signs of Osimertinib toxicity and consider dose reduction if concurrent use is unavoidable."
"Metronidazole inhibits CYP3A4, the primary enzyme responsible for the metabolism of ergotamine. Co-administration can lead to significantly elevated ergotamine plasma concentrations, increasing the risk of ergotism—a serious condition characterized by severe vasoconstriction, ischemia, and potential gangrene of the extremities. Patients may present with symptoms such as cold, painful extremities, muscle pain, and paresthesias, requiring immediate intervention."
"Levofloxacin and metronidazole both prolong the QT interval, and their concurrent use can lead to additive effects on cardiac repolarization. This increases the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Patients with pre-existing QT prolongation, electrolyte disturbances, or bradycardia are at higher risk."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRONIDAZOLE vs ANOQUAN, answered by our medical review team.
METRONIDAZOLE is a Nitroimidazole Antibiotic that works by After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.. ANOQUAN is a Local Anesthetic that works by Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRONIDAZOLE and ANOQUAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRONIDAZOLE is: 500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.. The standard adult dose of ANOQUAN is: 100 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRONIDAZOLE and ANOQUAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRONIDAZOLE is classified as Category A/B. Metronidazole crosses the placenta. First trimester: limited human data show no consistent increase in major malformations; however, some studies suggest a possible small risk of o. ANOQUAN is classified as Category C. Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.